22 research outputs found
AI-Enabled Lung Cancer Prognosis
Lung cancer is the primary cause of cancer-related mortality, claiming
approximately 1.79 million lives globally in 2020, with an estimated 2.21
million new cases diagnosed within the same period. Among these, Non-Small Cell
Lung Cancer (NSCLC) is the predominant subtype, characterized by a notably
bleak prognosis and low overall survival rate of approximately 25% over five
years across all disease stages. However, survival outcomes vary considerably
based on the stage at diagnosis and the therapeutic interventions administered.
Recent advancements in artificial intelligence (AI) have revolutionized the
landscape of lung cancer prognosis. AI-driven methodologies, including machine
learning and deep learning algorithms, have shown promise in enhancing survival
prediction accuracy by efficiently analyzing complex multi-omics data and
integrating diverse clinical variables. By leveraging AI techniques, clinicians
can harness comprehensive prognostic insights to tailor personalized treatment
strategies, ultimately improving patient outcomes in NSCLC. Overviewing
AI-driven data processing can significantly help bolster the understanding and
provide better directions for using such systems.Comment: This is the author's version of a book chapter entitled: "Cancer
Research: An Interdisciplinary Approach", Springe
Improving Radiotherapy in Immunosuppressive Microenvironments by Targeting Complement Receptor C5aR1
An immunosuppressive microenvironment causes poor tumor T cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses in these tumors is still a challenge. Using an integrated screening approach to identify cancer-specific vulnerabilities, we identified complement receptor C5aR1 as a druggable target, which when inhibited improved radiotherapy, even in tumors displaying immunosuppressive features and poor CD8+ T cell infiltration. While C5aR1 is well-known for its role in the immune compartment, we found that C5aR1 is also robustly expressed on malignant epithelial cells, highlighting potential tumor cell-specific functions. C5aR1 targeting resulted in increased NF-κB-dependent apoptosis specifically in tumors and not normal tissues, indicating that, in malignant cells, C5aR1 primarily regulated cell fate. Collectively, these data revealed that increased complement gene expression is part of the stress response mounted by irradiated tumors and that targeting C5aR1 could improve radiotherapy, even in tumors displaying immunosuppressive features
Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication
Pharmacological targeting of metabolic processes in cancer must overcome redundancy in biosynthetic pathways. Deoxycytidine (dC) triphosphate (dCTP) can be produced both by the de novo pathway (DNP) and by the nucleoside salvage pathway (NSP). However, the role of the NSP in dCTP production and DNA synthesis in cancer cells is currently not well understood. We show that acute lymphoblastic leukemia (ALL) cells avoid lethal replication stress after thymidine (dT)-induced inhibition of DNP dCTP synthesis by switching to NSP-mediated dCTP production. The metabolic switch in dCTP production triggered by DNP inhibition is accompanied by NSP up-regulation and can be prevented using DI-39, a new high-affinity small-molecule inhibitor of the NSP rate-limiting enzyme dC kinase (dCK). Positron emission tomography (PET) imaging was useful for following both the duration and degree of dCK inhibition by DI-39 treatment in vivo, thus providing a companion pharmacodynamic biomarker. Pharmacological co-targeting of the DNP with dT and the NSP with DI-39 was efficacious against ALL models in mice, without detectable host toxicity. These findings advance our understanding of nucleotide metabolism in leukemic cells, and identify dCTP biosynthesis as a potential new therapeutic target for metabolic interventions in ALL and possibly other hematological malignancies
Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography
Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure-activity relationship study was carried out. Positron Emission Tomography (PET) using (18)F-L-1-(2′-deoxy-2′-FluoroArabinofuranosyl) Cytosine ((18)F-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC(50) = ∼1 – 12 nM) using the (18)F-L-FAC PET pharmacodynamic assay identified compounds demonstrating superior in vivo efficacy
Circadian rhythms and glucocorticoids in a cell culture model of bipolar disorder
Circadian rhythms are endogenous biological rhythms that oscillate on a 24-hour period. Dysfunction in the circadian system has been implicated in mood disorders, including bipolar disorder (BD). While genetics can explain 60-80% of the variance in expression of this disorder, 20-40% is unaccounted for and could be due to psychosocial factors such as stress. We hypothesized that cells from patients with BD would be more susceptible to rhythm alterations than those of healthy controls when exposed to conditions modeling stress. In order to explore our hypothesis we employed dexamethasone, a synthetic version of the glucocorticoid hormones that are released in response to stress via the hypothalamic-pituitary- adrenal axis. We used qPCR to examine expression of genes indicating cellular stress and bioluminescent reporter assays of clock gene expression to examine circadian rhythm parameters of period, amplitude, and goodness-of- fit. We report that there are no differences in response to dexamethasone between the control and BD cells for period and amplitude. However, we found significant differences in goodness-of-fit, suggesting that glucocorticoid mediated stress could provoke symptoms of BD through a circadian clock mechanis
From Eyes to Cameras: Computer Vision for High-Throughput Liquid-Liquid Separation
We present a modular, high-throughput (HT) automation platform for screening Liquid-Liquid Extraction (LLE) workup processes. Our automated hardware platform simultaneously screens up to 12 vials, and is coupled with a computer vision (CV) system for real-time monitoring of macroscopic visual cues. Our CV system, named HeinSight3.0, leverages machine learning and image analysis to classify and quantify multivariate visual cues such as liquid level, phase split clarity, turbidity, homogeneity, volume, and color. These cues, combined with process parameters like stir rate and temperature, enable real-time analysis of key workup processes (e.g., separation time, phase split quality, volume ratio of layers, color, and emulsion presence) to aid in the optimization of separation parameters. We demonstrate our system on three case-studies: impurity recovery, excess reagent removal, and Grignard workup. Our application of HeinSight3.0 on literature data also suggests high potential for generalizability and adaptability across different platforms and contexts. Overall, our work represents a significant step towards achieving end-to-end autonomous LLE screening guided by visual cues, contributing to the realization of a self-driving lab for workup processes
Recommended from our members
Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.
Combined inhibition of ribonucleotide reductase and deoxycytidine kinase (dCK) in multiple cancer cell lines depletes deoxycytidine triphosphate pools leading to DNA replication stress, cell cycle arrest, and apoptosis. Evidence implicating dCK in cancer cell proliferation and survival stimulated our interest in developing small molecule dCK inhibitors. Following a high throughput screen of a diverse chemical library, a structure-activity relationship study was carried out. Positron Emission Tomography (PET) using (18)F-L-1-(2-deoxy-2-FluoroArabinofuranosyl) Cytosine ((18)F-L-FAC), a dCK-specific substrate, was used to rapidly rank lead compounds based on their ability to inhibit dCK activity in vivo. Evaluation of a subset of the most potent compounds in cell culture (IC50 = ∼1-12 nM) using the (18)F-L-FAC PET pharmacodynamic assay identified compounds demonstrating superior in vivo efficacy
Recommended from our members
Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.
Pharmacological targeting of metabolic processes in cancer must overcome redundancy in biosynthetic pathways. Deoxycytidine (dC) triphosphate (dCTP) can be produced both by the de novo pathway (DNP) and by the nucleoside salvage pathway (NSP). However, the role of the NSP in dCTP production and DNA synthesis in cancer cells is currently not well understood. We show that acute lymphoblastic leukemia (ALL) cells avoid lethal replication stress after thymidine (dT)-induced inhibition of DNP dCTP synthesis by switching to NSP-mediated dCTP production. The metabolic switch in dCTP production triggered by DNP inhibition is accompanied by NSP up-regulation and can be prevented using DI-39, a new high-affinity small-molecule inhibitor of the NSP rate-limiting enzyme dC kinase (dCK). Positron emission tomography (PET) imaging was useful for following both the duration and degree of dCK inhibition by DI-39 treatment in vivo, thus providing a companion pharmacodynamic biomarker. Pharmacological co-targeting of the DNP with dT and the NSP with DI-39 was efficacious against ALL models in mice, without detectable host toxicity. These findings advance our understanding of nucleotide metabolism in leukemic cells, and identify dCTP biosynthesis as a potential new therapeutic target for metabolic interventions in ALL and possibly other hematological malignancies